SOUTH KOREA · OPENDART
Ensol Biosciences Inc.
엔솔바이오사이언스 · 140610 · KONEX
Score
Not ranked: no net buying on the exchange by an individual insider in the last 180 days.
Insider trades on the exchange
Purchases and sales on the exchange in the last 12 months. The filing gives the settlement date; the trade date is two trading days earlier.
| Trade date | Insider | Role | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-03-16 | Namdeug Jeon | Managing director | Sold on the exchange | 100 | ₩15,400 | ₩1.5M | DART ↗ |
| 2026-03-13 | Namdeug Jeon | Managing director | Sold on the exchange | 5,429 | ₩14,767 | ₩80.2M | DART ↗ |
| 2026-03-12 | Namdeug Jeon | Managing director | Sold on the exchange | 2,715 | ₩14,527 | ₩39.4M | DART ↗ |
| 2026-03-11 | Namdeug Jeon | Managing director | Sold on the exchange | 956 | ₩14,514 | ₩13.9M | DART ↗ |
| 2026-03-10 | Namdeug Jeon | Managing director | Sold on the exchange | 800 | ₩14,750 | ₩11.8M | DART ↗ |
Other changes in holdings · 8
Option exercises, grants, new shares, inheritance, gifts, off-exchange trades and trades by companies and funds. Not counted in the score.
| Date | Insider | Role | Reason | Shares | Filing |
|---|---|---|---|---|---|
| 2026-03-19 | Eun-Joung Moon | Vice president | Stock options(+) | 1,396 | DART ↗ |
| 2026-03-19 | Namdeug Jeon | Managing director | Stock options(+) | 10,000 | DART ↗ |
| 2025-07-18 | HYUNG INWOO | 10% shareholder | Paid-in capital increase by third-party allotment(+) | 789,140 | DART ↗ |
| 2025-06-11 | HYUNG INWOO | 10% shareholder | Acquisition in OTC(+) | 810,860 | DART ↗ |
| 2025-01-31 | HYUNG INWOO | 10% shareholder | Acquisition of paid-in new shares(+) | 1,180,637 | DART ↗ |
| 2025-01-02 | HYUNG INWOO | 10% shareholder | Acquisition in OTC(+) | 550,055 | DART ↗ |
| 2025-01-02 | Hae-jin Kim | CEO | 장외매수(+) | 550,055 | DART ↗ |
| 2025-01-02 | Hae-jin Kim | CEO | 장외매도(-) | 550,055 | DART ↗ |